---
title: Rebalance neurotransmitter precursors with supplement
nct_id: NCT07115563
phase: NA
status: RECRUITING
sponsor: Cristina Colon-Semenza
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07115563"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07115563"
last_fetched: "2026-05-10T14:05:29.216Z"
source: "Parkinson's Pathways (curated)"
---
# Rebalance neurotransmitter precursors with supplement

**Goal (in five words):** Rebalance neurotransmitter precursors with supplement

**Official Title:** Effects of Targeted Amino Acid Supplementation for People With Parkinson's Disease on Amino Acid Profiles and Health Related Markers

**Trial ID:** [NCT07115563](https://clinicaltrials.gov/study/NCT07115563)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Cristina Colon-Semenza
- **Target Enrollment:** 30 participants
- **Start Date:** 2025-10-31
- **Completion Date:** 2027-09
- **Conditions:** Parkinson Disease (PD)
- **Interventions:** Targeted Amino Acid Supplement, Control (placebo)
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

The goal is to find out whether a targeted blend of amino acids can change blood amino acid profiles and related health markers in people with Parkinson's, which might influence neurotransmitter balance and overall metabolism. The approach gives a daily supplement of selected amino acids versus placebo, aiming to boost or rebalance precursors for neurotransmitters and protein synthesis, and the study will watch for interactions with levodopa because some amino acids can compete with it for transport into the brain. Participants should be age 60 to 80 with idiopathic Parkinson's, on dopamine replacement therapy like levodopa for at least two years and on a stable dose for three months, with exclusions for significant cognitive impairment, deep brain stimulation, bleeding disorders, or other unstable medical issues.

## Eligibility

- **Minimum age:** 60 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusionary Criteria:

* Male and Females.
* 60-80 Years.
* Previous diagnosis of idiopathic Parkinson's Disease by patient report.
* Use of dopamine replacement medication (e.g. levodopa) for at least 2 years.
* On a stable dose of dopamine replacement medication for at least 3 months with no plans for change in the next two months.

Exclusionary criteria

* Apparent cognitive impairment as determined by phone screening (Telephone Interview for Cognitive Status \<29).
* Diagnosis of Parkinsonism or atypical Parkinson's Disease.
* Prescription of Dopamine antagonist.
* Any unstable medical condition.
* Any known bleeding disorder or current consumption of blood thinners.
* Use of Deep Brain Stimulation.
* Gastric or Bowel resection surgery.
* Contraindications to blood draw.
```

## Locations (1)

- University of Connecticut, Storrs, Connecticut, United States _(41.8084, -72.2495)_
  - Jacob Earp, MS — (CONTACT) — 860-486-2671 — jacob.earp@uconn.edu
  - Carlos Rehbein — (CONTACT) — carlos.rehbein@uconn.edu
  - Jacob Earp, PhD — (PRINCIPAL_INVESTIGATOR)
  - Cristina Colon-Semenza, PT, MPT, PhD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Carlos Rehbein, MS — (CONTACT) — 860-486-1121 — carlos.rehbein@uconn.edu

---

*Canonical: https://parkinsonspathways.com/trial/NCT07115563*  
*HTML version: https://parkinsonspathways.com/trial/NCT07115563*  
*Source data: https://clinicaltrials.gov/study/NCT07115563*